Worldwide Medical Devices (WMD) manufactures medical diagnostic equipment at sev
ID: 1172381 • Letter: W
Question
Worldwide Medical Devices (WMD) manufactures medical diagnostic equipment at several locations across Europe. WMD has traditionally manufactured high-quality large medical equipment for use in hospitals. Recently, the firm has developed a new technology that makes testing vitamin D deficiency at GP surgeries affordable, avoiding the need to send patients’ blood to testing laboratories. WMD has spent £50m designing and developing this new generation of equipment for the European domestic market. The costs to complete the final stages of regulatory approval are estimated to be £30m. WMD plan to establish a new division, Fast Medical Diagnostics (FMD), to manufacture and market this new generation of testing devices. This will be WMD’s first venture into the smaller equipment market. WMD will continue to manufacture their larger hospital equipment separately. This new generation of testing devices is expected to have a production life of six years. The Group Finance Director is busy arranging a new debtfacility for WMD and has asked you to prepare an investment appraisal report to present to the next board meeting which will make a recommendation to the directors whether to proceed with establishing FMD. The new FMD factory would be built on a vacant site already owned by WMD adjacent to their existing Lyon factory. The vacant site was recently valued at £6m. Investment to build the factory and the required plant and equipment would be £300m. WMD charges depreciation on a straight-line basis over the useful life of assets. The plant and equipment is not expected to have any scrap value at the end of the project. The project will also require additional working capital of £60m for the life of the project. It is expected that 60% of the working capital investment will be recovered at the end of the project. Currently, net investment in plant and equipment is eligible for capital allowances on a straight-line basis over four years. The applicable corporation tax rate is 30% and paid one year in arrears. Capital allowances are received by WMD in the same year that they are claimed. FMD expects to sell a total of 100,000 of the devices each year at a fixed price of £3,200 per device over the planned production life of six years. Incremental operating costs for FMD are estimated to be £220m per annum. All cash flows are in today’s money and inflation is expected to be 2.5% per annum over the next six years. WMD’s shares continue to be listed on the London Stock Exchange where they currently trade at £3.50 with an equity beta of 1.6. The expected equity risk premium is 8% and risk-free rate is 2%. WMD currently has a market gearing ratio (debt / [debt+equity]) of 30%. WMD has sufficient resources available to fund the FMD project from current facilities. The current average before-tax cost of borrowing for the company is 5%.
I have already calculated the WACC. I am just looking for the cash flows computation(Capital allowance, working cap, etc...). Thank you
Explanation / Answer
50
Cost of Plant and equipment 300 Plant and equipment scrap value 0 Life of equipments (yr) 6 Additional working capital 60 Total cost of the project = Cost of Plant and equipment + Additional working capital = 300+60= 360 Revenue generated at the end of the project 60 of the total cost of the project = 60% of 360 = 216Related Questions
drjack9650@gmail.com
Navigate
Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.